Amgen Cdr Stock Net Income
| AMGN Stock | 27.85 0.30 1.09% |
As of the 6th of February, Amgen CDR shows the mean deviation of 1.42, and Risk Adjusted Performance of 0.0665. Amgen CDR technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Amgen CDR Total Revenue |
|
Market Capitalization 178.5 B | Earnings Share 12.9373 |
| Last Reported | Projected for Next Year | ||
| Net Income Applicable To Common Shares | 7.7 B | 6.9 B | |
| Net Income | 3.7 B | 4.6 B |
Amgen | Net Income |
Evaluating Amgen CDR's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Amgen CDR's fundamental strength.
Latest Amgen CDR's Net Income Growth Pattern
Below is the plot of the Net Income of Amgen CDR over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Amgen CDR financial statement analysis. It represents the amount of money remaining after all of Amgen CDR operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Amgen CDR's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amgen CDR's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 4.09 B | 10 Years Trend |
|
Net Income |
| Timeline |
Amgen Net Income Regression Statistics
| Arithmetic Mean | 6,505,191,176 | |
| Geometric Mean | 6,462,979,245 | |
| Coefficient Of Variation | 10.53 | |
| Mean Deviation | 284,140,138 | |
| Median | 6,552,000,000 | |
| Standard Deviation | 685,193,264 | |
| Sample Variance | 469489.8T | |
| Range | 3.6B | |
| R-Value | (0.06) | |
| Mean Square Error | 499222.9T | |
| R-Squared | 0 | |
| Significance | 0.83 | |
| Slope | (7,588,235) | |
| Total Sum of Squares | 7511836.9T |
Amgen Net Income History
Amgen CDR 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Amgen CDR's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Amgen CDR.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in Amgen CDR on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding Amgen CDR or generate 0.0% return on investment in Amgen CDR over 90 days. Amgen CDR is related to or competes with Maple Leaf, Nicola Mining, Capstone Mining, MTY Food, Rockpoint Gas, Vizsla Silver, and Information Services. Amgen CDR is entity of Canada. It is traded as Stock on TO exchange. More
Amgen CDR Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Amgen CDR's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Amgen CDR upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.91 | |||
| Information Ratio | 0.0584 | |||
| Maximum Drawdown | 8.71 | |||
| Value At Risk | (3.38) | |||
| Potential Upside | 4.04 |
Amgen CDR Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Amgen CDR's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Amgen CDR's standard deviation. In reality, there are many statistical measures that can use Amgen CDR historical prices to predict the future Amgen CDR's volatility.| Risk Adjusted Performance | 0.0665 | |||
| Jensen Alpha | 0.1465 | |||
| Total Risk Alpha | 0.0596 | |||
| Sortino Ratio | 0.0637 | |||
| Treynor Ratio | 0.5262 |
Amgen CDR February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0665 | |||
| Market Risk Adjusted Performance | 0.5362 | |||
| Mean Deviation | 1.42 | |||
| Semi Deviation | 1.72 | |||
| Downside Deviation | 1.91 | |||
| Coefficient Of Variation | 1250.35 | |||
| Standard Deviation | 2.09 | |||
| Variance | 4.36 | |||
| Information Ratio | 0.0584 | |||
| Jensen Alpha | 0.1465 | |||
| Total Risk Alpha | 0.0596 | |||
| Sortino Ratio | 0.0637 | |||
| Treynor Ratio | 0.5262 | |||
| Maximum Drawdown | 8.71 | |||
| Value At Risk | (3.38) | |||
| Potential Upside | 4.04 | |||
| Downside Variance | 3.66 | |||
| Semi Variance | 2.94 | |||
| Expected Short fall | (1.56) | |||
| Skewness | 0.7948 | |||
| Kurtosis | 2.87 |
Amgen CDR Backtested Returns
As of now, Amgen Stock is very steady. Amgen CDR secures Sharpe Ratio (or Efficiency) of 0.08, which signifies that the company had a 0.08 % return per unit of standard deviation over the last 3 months. We have found twenty-seven technical indicators for Amgen CDR, which you can use to evaluate the volatility of the firm. Please confirm Amgen CDR's risk adjusted performance of 0.0665, and Mean Deviation of 1.42 to double-check if the risk estimate we provide is consistent with the expected return of 0.17%. Amgen CDR has a performance score of 6 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.3, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Amgen CDR's returns are expected to increase less than the market. However, during the bear market, the loss of holding Amgen CDR is expected to be smaller as well. Amgen CDR right now shows a risk of 2.09%. Please confirm Amgen CDR coefficient of variation, jensen alpha, and the relationship between the downside deviation and information ratio , to decide if Amgen CDR will be following its price patterns.
Auto-correlation | -0.32 |
Poor reverse predictability
Amgen CDR has poor reverse predictability. Overlapping area represents the amount of predictability between Amgen CDR time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Amgen CDR price movement. The serial correlation of -0.32 indicates that nearly 32.0% of current Amgen CDR price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.32 | |
| Spearman Rank Test | -0.06 | |
| Residual Average | 0.0 | |
| Price Variance | 0.43 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Amgen Interest Income
Based on the recorded statements, Amgen CDR reported net income of 4.09 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers - General industry. The net income for all Canada stocks is significantly lower than that of the firm.
Amgen Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Amgen CDR's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Amgen CDR could also be used in its relative valuation, which is a method of valuing Amgen CDR by comparing valuation metrics of similar companies.Amgen CDR is currently under evaluation in net income category among its peers.
Amgen Fundamentals
| Return On Equity | 81.71 | ||||
| Revenue | 36.75 B | ||||
| Net Income | 4.09 B | ||||
| Cash And Equivalents | 9.13 B | ||||
| Total Debt | 81.93 B | ||||
| Cash Flow From Operations | 11.49 B | ||||
| Earnings Per Share | 12.94 X | ||||
| Number Of Employees | 28 K | ||||
| Market Capitalization | 178.5 B | ||||
| Total Asset | 90.59 B | ||||
| Retained Earnings | (27.59 B) | ||||
| Net Asset | 90.59 B |
About Amgen CDR Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Amgen CDR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amgen CDR using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amgen CDR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Amgen CDR
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen CDR position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen CDR will appreciate offsetting losses from the drop in the long position's value.Moving against Amgen Stock
| 0.6 | DR | Medical Facilities | PairCorr |
| 0.52 | AUUA | Aluula Composites Earnings Call This Week | PairCorr |
| 0.51 | GMA | Geomega Resources | PairCorr |
| 0.49 | MRK | Merck | PairCorr |
| 0.47 | LLY | Eli Lilly | PairCorr |
The ability to find closely correlated positions to Amgen CDR could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen CDR when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen CDR - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen CDR to buy it.
The correlation of Amgen CDR is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen CDR moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen CDR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amgen CDR can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Amgen Stock
Amgen CDR financial ratios help investors to determine whether Amgen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amgen with respect to the benefits of owning Amgen CDR security.